Glenmede Trust’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Glenmede Trust’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-8	Closed	-$1K	–	2765
2015 Q4	$1K	Sell	8 -6	-43%	-$1.2K	﹤0.01%	2595
2015 Q3	$2K	Hold	14	–	–	﹤0.01%	2541
2015 Q2	$13K	Hold	14	–	–	﹤0.01%	2050
2015 Q1	$10K	Sell	14 -3	-18%	-$2.25K	﹤0.01%	2131
2014 Q4	$13K	Hold	17	–	–	﹤0.01%	2157
2014 Q3	$6K	Buy	17 +13	+325%	+$3.48K	﹤0.01%	2214
2014 Q2	$1K	Sell	4 -6	-60%	-$1.29K	﹤0.01%	2292
2014 Q1	$2K	Buy	+10	New	+$2.79K	﹤0.01%	2253

Other funds holding TTPH

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Glenmede Trust's TTPH Position: Q1 2016 in Review

Glenmede Trust sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q1 2016, closing a stake of 8 shares — an estimated $1K sold.

Glenmede Trust first reported a position in TTPH in Q1 2014 and held it in 8 quarters. The position peaked at $13K in Q2 2015. 101 funds tracked by Wall St. Rank hold TTPH as of Q1 2016.

Glenmede Trust reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q1 2016 after selling out during the quarter.
Glenmede Trust sold 8 Tetraphase Pharmaceuticals, Inc. shares in Q1 2016, an estimated $1K.
Glenmede Trust first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 8 quarters.
Glenmede Trust's Tetraphase Pharmaceuticals, Inc. position peaked at $13K in Q2 2015.
101 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q1 2016.

Based on Glenmede Trust's 13F filing for Q1 2016, filed 26 Apr 2016.